Perspective Therapeutics, Inc.
HealthcareAMEX:CATX · New York Stock Exchange American
-$0.02 today
Vol 0.94M · Avg 1.44M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-49.8%
avg -49.3%
ROIC
-47.2%
avg -41.8%
ROA
-38.6%
avg -38.3%
Analysis
ROA is currently the strongest return metric at -38.6% versus its period average of -38.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Johan Spoor | Chief Executive Officer & Director | $1.10M | — | 54 | $735,000.00 | 0.95% |
Markus Puhlmann | Chief Medical Officer | $737,400.00 | — | 60 | $150,000.00 | 0.19% |
Jonathan R. Hunt | Chief Accounting Officer | $611,165.00 | — | 59 | $90,000.00 | 0.12% |
Joel David Sendek | CFO & Principal Financial Officer | $574,294.00 | — | 59 | $600,000.00 | 0.78% |
Michael K. Schultz | Chief Science Officer | — | — | — | — | — |
Amos Hedt PGradDip | Chief Business Strategy Officer | — | — | — | — | — |
Andrew Bright | Executive Vice President of Brachytherapy | — | — | — | — | — |
Chris Nenno | General Counsel & Corporate Secretary | — | — | — | — | — |
Shane Cobb | Executive Vice President of Operations | — | — | — | — | — |
Annie J. Cheng | Vice President of Investor Relations | — | — | 50 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$42,240.60
Sells
0
$0.00
Net Sentiment
+$42,240.60
Net buying
Most Active
Hunt Jonathan Robert
1 transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| Nov 13, 2025 | Hunt Jonathan Robert Direct | Buy | 11.0K | $2.03 | $22,294.80 | |
| Nov 12, 2025 | Williamson Robert F III Indirect | Buy | 9.5K | $2.10 | $19,945.80 |
Analysis
Insiders reported 2 buys worth $42,240.60 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $42,240.60. Hunt Jonathan Robert was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A3 analysts |
| Revenue | N/A | N/A | +1.8% | +33.1% (15yr)4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Recent growth has been strongest in Revenue at +1.8% over three years. Forward estimates point to Revenue at +33.1% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Anteris Technologies Global Corp.
NASDAQ:AVR
$336.61M
Electromed, Inc.
AMEX:ELMD
$307.52M
Profound Medical Corp.
NASDAQ:PROF
$200.47M
TriSalus Life Sciences, Inc.
NASDAQ:TLSI
$142.92M
Nano-X Imaging Ltd.
NASDAQ:NNOX
$122.48M
MaxCyte, Inc.
NASDAQ:MXCT
$119.98M
Invivyd, Inc.
NASDAQ:IVVD
$102.20M
Neuronetics, Inc.
NASDAQ:STIM
$92.55M
Solana Company
NASDAQ:HSDT
$89.92M
Nyxoah S.A.
NASDAQ:NYXH
$55.05M
Who manages CATX?
Perspective Therapeutics, Inc. (CATX) lists 10 active executives. The top listed executive is Michael K. Schultz, Chief Science Officer.
Are CATX insiders buying or selling?
Recent insider activity shows net buying of $81.20M.
Explore More
Continue the stock analysis
Jump to another research area for this company.